Following 2.5 to 25mg once daily dosing , TA-8995 demonstrated nearly complete inhibition of CETP activity ( 92-99 % ) , increased high density lipoprotein-cholesterol ( HDL-C ) by 96 to 140 % and decreased low density liporotein-cholesterol ( LDL-C ) by 40 % to 53 % .